Immunome, Inc.

NasdaqCM:IMNM Stock Report

Market Cap: US$2.8b

Immunome Management

Management criteria checks 4/4

Immunome's CEO is Clay Siegall, appointed in Oct 2023, has a tenure of 2.75 years. total yearly compensation is $7.68M, comprised of 9.6% salary and 90.4% bonuses, including company stock and options. directly owns 0.61% of the company’s shares, worth $16.85M. The average tenure of the management team and the board of directors is 2.6 years and 3.9 years respectively.

Key information

Clay Siegall

Chief executive officer

US$7.7m

Total compensation

CEO salary percentage9.57%
CEO tenure2.8yrs
CEO ownership0.6%
Management average tenure2.6yrs
Board average tenure3.9yrs

Recent management updates

Recent updates

Analysis Article • Jun 20

Immunome (IMNM) Stock Could Be Below Fair Value After Phase 1 Trial Start

Immunome (IMNM) recently dosed the first patient in a Phase 1, first in human trial of IM-1617. This is an antibody drug conjugate for advanced solid tumors that uses the company’s proprietary TOP1 inhibitor payload. See our latest analysis for Immunome. For Immunome, the IM-1617 trial update arrives after a mixed period for the stock, with the share price down 18.38% over the past 30 days but a very strong 114.17% total shareholder return over the last year. This hints that long term...
Seeking Alpha • Jan 30

Immunome Can Take The Fight To Competitors With Varegacestat

Summary Immunome's varegacestat is in a phase 3 trial in patients with desmoid tumors that should produce results in H2'25. Varegacestat offers potential advantages, such as once-daily dosing, over SWTX's already-marketed drug for desmoid tumors, Ogsiveo. IMNM's announcement of a plan to offer $125M of common stock could provide a dip in the stock, but would provide more funds to develop its pipeline of antibody-drug conjugates. Read the full article on Seeking Alpha
Seeking Alpha • Dec 11

Immunome: A Recently Acquired Lead Asset And A Small Market

Summary Immunome's lead asset, AL102, is in a Phase 3 trial for desmoid tumors, showing promising ORR compared to the approved OGSIVEO. Immunome has a turbulent history, shifting focus from COVID-19 therapies to oncology, and acquiring AL102 from Ayala Therapeutics. Financially, Immunome has a market cap of $867mn and a cash runway of 4-5 quarters, risking dilution before drug launch. Despite the potential, IMNM's current market cap already reflects the risk-adjusted value of AL102, making it an avoid for now. Read the full article on Seeking Alpha
Seeking Alpha • Jan 18

Immunome: Why It Has Doubled Over The Last Month

Summary Immunome has experienced a meteoric rise in market capitalization without any pipeline drugs reaching clinical trials. The company's pipeline includes IM-1021, an antibody-drug conjugate targeting ROR1, and IM-4320, a monoclonal antibody targeting IL-38. IMNM's financial overview shows a cash runway of approximately 5 years, but the long wait time for clinical trials poses a significant risk. Read the full article on Seeking Alpha
Analysis Article • Mar 17

Will Immunome (NASDAQ:IMNM) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Nov 20

Is Immunome (NASDAQ:IMNM) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Aug 05

Immunome GAAP EPS of -$0.74

Immunome press release (NASDAQ:IMNM): Q2 GAAP EPS of -$0.74. As of June 30, 2022, cash and cash equivalents totaled $34.6 million.
Analysis Article • Aug 05

Here's Why We're Watching Immunome's (NASDAQ:IMNM) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Jun 30

Immunome gains 34% after preclinical data on COVID-19 antibody

Clinical-stage biotech Immunome (NASDAQ:IMNM) added ~34% on Thursday on the publication of research indicating that the company’s experimental three-antibody cocktail IMM-BCP-01 was effective against COVID-19 variants of concern including BA.1 and BA.2. IMM-BCP-01 consists of three patient-derived neutralizing antibodies, designed to target non-overlapping regions on the   SARS-CoV-2 spike protein. According to results published in the journal science, IMM-BCP-01 was found to have decreased Omicron infection in the lungs of Syrian golden hamsters. The lab results have also indicated potential antiviral effector response, including phagocytosis, antibody-mediated cellular cytotoxicity, complement pathway activation. Results indicate that “IMM-BCP-01 could be a promising means for preventing or treating infection of SARS-CoV-2 variants of concern, including Omicron BA.1 and BA.2, in susceptible individuals,” researchers wrote. Early this month, Immunome (IMNM) announced the dosing initiation of an early-stage study for IMM-BCP-01 involving recently diagnosed COVID-19 patients. The topline data from the single dose, dose escalation study is expected in 2H 2022.

CEO Compensation Analysis

How has Clay Siegall's remuneration changed compared to Immunome's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$225m

Dec 31 2025US$8mUS$735k

-US$212m

Sep 30 2025n/an/a

-US$223m

Jun 30 2025n/an/a

-US$212m

Mar 31 2025n/an/a

-US$205m

Dec 31 2024US$9mUS$700k

-US$293m

Sep 30 2024n/an/a

-US$305m

Jun 30 2024n/an/a

-US$263m

Mar 31 2024n/an/a

-US$232m

Dec 31 2023US$16mUS$163k

-US$107m

Compensation vs Market: Clay's total compensation ($USD7.68M) is about average for companies of similar size in the US market ($USD6.91M).

Compensation vs Earnings: Clay's compensation has been consistent with company performance over the past year.

CEO

Clay Siegall (65 yo)

2.8yrs
Tenure
US$7,682,601
Compensation

Dr. Clay B. Siegall, Ph D., serves as a Special Partner at Arsenal Bridge Ventures. Dr. Siegall served as an Independent Chairman since December 13, 2023 until October 28, 2025 at Tourmaline Bio, Inc. Dr....

Leadership Team

NamePositionTenureCompensationOwnership
Clay Siegall
Chairman2.8yrsUS$7.68m0.61%
$ 16.8m
Max Rosett
Chief Financial Officer2.5yrsUS$2.79m0.048%
$ 1.3m
Robert Lechleider
Chief Medical Officer2.8yrsUS$2.75m0.014%
$ 385.6k
Philip Tsai
Chief Technical Officer2.1yrsno data0.038%
$ 1.1m
Jack Higgins
Chief Scientific Officer2.8yrsUS$2.17m0.022%
$ 609.6k
Sandra Stoneman
Chief Legal Officer5.8yrsUS$5.25m0.0049%
$ 135.6k
Kinney Horn
Chief Business Officer2.4yrsUS$6.99m0%
$ 0
Roee Shahar
Executive Vice President of Commercial1.8yrsno datano data
2.6yrs
Average Tenure
53yo
Average Age

Experienced Management: IMNM's management team is considered experienced (2.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Clay Siegall
Chairman2.8yrsUS$7.68m0.61%
$ 16.8m
Louis Weiner
Member of Scientific Advisory Boardno datano datano data
Philip Wagenheim
Independent Director8.6yrsUS$175.00k0.30%
$ 8.3m
George Prendergast
Member of Scientific Advisory Boardno datano datano data
Anthony Tolcher
Member of Scientific Advisory Board and Member of ADC & T Cell Redirection Advisory Boardno datano datano data
Isaac Barchas
Lead Independent Director2.8yrsUS$210.00k0.081%
$ 2.2m
James Boylan
Independent Director2.8yrsUS$190.00k0%
$ 0
Andrew Badley
Member of COVID-19 Advisory Board5.1yrsno datano data
Carol Schafer
Independent Director2.5yrsUS$195.00k0%
$ 0
William Strohl
Member of Scientific Advisory Boardno datano datano data
Shmuel Shoham
Member of COVID-19 Advisory Board5.8yrsno datano data
Susan Weiss
Member of COVID-19 Advisory Board5.8yrsno datano data
3.9yrs
Average Tenure
62yo
Average Age

Experienced Board: IMNM's board of directors are considered experienced (3.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/08 22:36
End of Day Share Price 2026/07/08 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Immunome, Inc. is covered by 15 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Lukas ShumwayBarclays
Adam VogelCraig-Hallum Capital Group LLC
Cory KasimovEvercore ISI